Compare MRKR & BRFH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRKR | BRFH |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 18.4M |
| IPO Year | 2010 | 2010 |
| Metric | MRKR | BRFH |
|---|---|---|
| Price | $0.95 | $0.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $7.87 | $4.00 |
| AVG Volume (30 Days) | ★ 60.0K | 31.0K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.61 | 10.53 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $211,467.00 |
| Revenue This Year | $19.61 | $60.90 |
| Revenue Next Year | $375.85 | $27.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 92.09 |
| 52 Week Low | $0.84 | $0.77 |
| 52 Week High | $2.46 | $3.74 |
| Indicator | MRKR | BRFH |
|---|---|---|
| Relative Strength Index (RSI) | 31.50 | 26.85 |
| Support Level | N/A | $0.77 |
| Resistance Level | $1.31 | $1.45 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 5.58 | 14.51 |
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Barfresh Food Group Inc develops, manufactures and distributes ready to blend frozen beverages, including smoothies, shakes and frappes for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient, and without waste. Barfresh provides both a single serve solution and a bulk format solution, ideal for high-volume locations. It has seven flavors available as part of its standard line vanilla shake, caribbean smoothie, triple berry smoothie, caramel macchiato frappe, strawberry banana smoothie, mocha frappe and mango burst smoothie and has the development capabilities to deliver custom flavors.